415 related articles for article (PubMed ID: 31490549)
1. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
2. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
4. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
[TBL] [Abstract][Full Text] [Related]
5. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.
Bowers LW; Cavazos DA; Maximo IX; Brenner AJ; Hursting SD; deGraffenried LA
Breast Cancer Res; 2013; 15(4):R59. PubMed ID: 23880059
[TBL] [Abstract][Full Text] [Related]
6. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
7. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
8. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
9. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
[TBL] [Abstract][Full Text] [Related]
10. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells.
Santen RJ; Fan P; Zhang Z; Bao Y; Song RX; Yue W
Steroids; 2009 Jul; 74(7):586-94. PubMed ID: 19138696
[TBL] [Abstract][Full Text] [Related]
11. IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation.
Zheng Y; Sowers JY; Houston KD
Front Endocrinol (Lausanne); 2020; 11():233. PubMed ID: 32435229
[TBL] [Abstract][Full Text] [Related]
12. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
13. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
[TBL] [Abstract][Full Text] [Related]
14. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Hou X; Huang F; Macedo LF; Harrington SC; Reeves KA; Greer A; Finckenstein FG; Brodie A; Gottardis MM; Carboni JM; Haluska P
Cancer Res; 2011 Dec; 71(24):7597-607. PubMed ID: 22042792
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
Lam L; Hu X; Aktary Z; Andrews DW; Pasdar M
Breast Cancer Res Treat; 2009 Dec; 118(3):605-21. PubMed ID: 19002577
[TBL] [Abstract][Full Text] [Related]
16. Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
Kruger DT; Beelen KJ; Opdam M; Sanders J; van der Noort V; Boven E; Linn SC
Br J Cancer; 2018 Oct; 119(7):832-839. PubMed ID: 30287915
[TBL] [Abstract][Full Text] [Related]
17. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
18. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.
Knowlden JM; Gee JM; Barrow D; Robertson JF; Ellis IO; Nicholson RI; Hutcheson IR
Breast Cancer Res; 2011 Sep; 13(5):R93. PubMed ID: 21939528
[TBL] [Abstract][Full Text] [Related]
19. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.
Chen J; Hou R; Zhang X; Ye Y; Wang Y; Tian J
PLoS One; 2014; 9(3):e91245. PubMed ID: 24618835
[TBL] [Abstract][Full Text] [Related]
20. IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells.
Vaziri-Gohar A; Zheng Y; Houston KD
Mol Cancer Res; 2017 Apr; 15(4):489-497. PubMed ID: 28096479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
